title: [Correction of cronic liver failure by transplantation of liver cells suspension and cell-engineering designs (experimental investigation)].
abstract: On an experimental model of chronic fibrotic liver damage (male rats Wistar (n-60), damage of CCl4, the duration of the experiment 90 days) it was studied the effectiveness of cell therapy for the correction of chronic liver failure. These rats were divided into 3 experimental groups: in the Ist-group (control, n=10) isotonic saline (650 mkl.) was injected; in the IInd-group (n=20) suspension of liver cells was applicated in a dose 8 - l0 x 10(6) cells; in the IIIrd-group (n=30) suspension of liver cells and bone marrow cells (mesenchymal stromal cells) in ratio 5:1 were used as cell associates on microparticles intjectable heterogeneous biopolymer hydrogel "SpheroGEL" (cell-engineering design) in common dose 8 - l0 x 10(6) It was ascertained that in the 2nd and in the 3rd groups the accelerated normalization of disturbed liver functional indices (ALT, AST, ALP) took place - to 30 days, but in the control group only to 90 days. The reliable differences in rats ofnormalization offunctional indices were absent between the IInd and the IIIrd groups. But in 90 days by using special histological dyeing it was found out that defibrotic processes in liver tissue were more expressed in the IIIrd group in comparison with the IIIrd group. Received results were consequence of prolonged vital activity of cells (liver cells and mesenchymal stromal bone marrow cells) into cell-engineering designs, which were transplanted in the IIIrd group. The obtained effect can be explained by that the developed cell-engineering designs provide adequate conditions for prolonged vital activity of the transplanted cells.
authors.forename: S V
authors.initials: SV
authors.lastname: Got'e
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Shagidulin
authors.forename: N A
authors.initials: NA
authors.lastname: Onishchenko
authors.forename: M E
authors.initials: ME
authors.lastname: Krasheninnikov
authors.forename: I M
authors.initials: IM
authors.lastname: Il'inskiĭ
authors.forename: N P
authors.initials: NP
authors.lastname: Mozheĭko
authors.forename: A V
authors.initials: AV
authors.lastname: Liundup
authors.forename: E A
authors.initials: EA
authors.lastname: Volkova
authors.forename: K I
authors.initials: KI
authors.lastname: Petrakov
authors.forename: P V
authors.initials: PV
authors.lastname: Avramov
authors.forename: N V
authors.initials: NV
authors.lastname: Perova
authors.forename: V I
authors.initials: VI
authors.lastname: Sevast'ianov
mesh_terms: D000818:Animals; D060846:Cell Engineering / Q000379:methods*; D017690:Cell Transplantation / Q000379:methods*; D004195:Disease Models, Animal; D058625:End Stage Liver Disease / Q000473:pathology / Q000601:surgery*; D005500:Follow-Up Studies; D022781:Hepatocytes / Q000166:cytology / Q000637:transplantation*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013535:Suspensions
chemical_list: D013535:Suspensions